Clinical characteristics and management of patients with mucopolysaccharidosis II in the United States enrolled in the Hunter Outcome Survey.
BACKGROUND In 2022, mucopolysaccharidosis II (MPS II) was added to the list of disorders recommended for inclusion in newborn screening panels in the USA; this is expected to substantially facilitate earlier diagnosis and treatment and improve patient outcomes. An analysis was conducted in US patients enrolled in the H...